395 related articles for article (PubMed ID: 30556449)
1. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
Massa H; Nagar AM; Vergados A; Dadoukis P; Patra S; Panos GD
J Int Med Res; 2019 Jan; 47(1):31-43. PubMed ID: 30556449
[TBL] [Abstract][Full Text] [Related]
2. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN
Mushtaq Y; Mushtaq MM; Gatzioufas Z; Ripa M; Motta L; Panos GD
Drug Des Devel Ther; 2023; 17():961-975. PubMed ID: 37020801
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Sanford M
Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
[TBL] [Abstract][Full Text] [Related]
5. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
6. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Panos GD; Arruti N; Patra S
Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
[TBL] [Abstract][Full Text] [Related]
7. ILUVIEN
Habib MS
Ther Deliv; 2018 Aug; 9(8):547-556. PubMed ID: 29943691
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
[TBL] [Abstract][Full Text] [Related]
10. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
11. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
12. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results.
Dobler E; Mohammed BR; Chavan R; Lip PL; Mitra A; Mushtaq B
Eye (Lond); 2023 Aug; 37(11):2310-2315. PubMed ID: 36513858
[TBL] [Abstract][Full Text] [Related]
14. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
[TBL] [Abstract][Full Text] [Related]
15. [Cost Comparison of Licensed Intravitreal Therapies for Insufficiently Anti-VEGF Responding Fovea Involving Diabetic Macular Edema in Germany].
Neubauer AS; Haritoglou C; Ulbig MW
Klin Monbl Augenheilkd; 2019 Feb; 236(2):180-191. PubMed ID: 29452450
[TBL] [Abstract][Full Text] [Related]
16. A review of therapies for diabetic macular oedema and rationale for combination therapy.
Amoaku WM; Saker S; Stewart EA
Eye (Lond); 2015 Sep; 29(9):1115-30. PubMed ID: 26113500
[TBL] [Abstract][Full Text] [Related]
17. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
18. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
[TBL] [Abstract][Full Text] [Related]
19. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Messenger WB; Beardsley RM; Flaxel CJ
Drug Des Devel Ther; 2013; 7():425-34. PubMed ID: 23737661
[TBL] [Abstract][Full Text] [Related]
20. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
